Provided by Tiger Fintech (Singapore) Pte. Ltd.

Marker Therapeutics, Inc.

1.56
+0.350028.93%
Post-market: 1.53-0.0301-1.93%19:57 EDT
Volume:2.01M
Turnover:3.07M
Market Cap:17.65M
PE:-1.16
High:1.82
Open:1.20
Low:1.20
Close:1.21
Loading ...

BRIEF-Marker Therapeutics Provides A Clinical Update On MT-601 In Patients With Lymphoma

Reuters
·
19 Dec 2024

BUZZ-Marker Therapeutics slides after $16 mln private placement

Reuters
·
19 Dec 2024

Marker Therapeutics sells 5.03M shares at $3.20 in private placement

TIPRANKS
·
19 Dec 2024

Marker Therapeutics provides update on MT-601 patients

TIPRANKS
·
19 Dec 2024

Marker Therapeutics Announces $16.1 Million Private Placement

THOMSON REUTERS
·
19 Dec 2024

Marker Therapeutics Announces $16.1 Million Private Placement

GlobeNewswire
·
19 Dec 2024

Marker Therapeutics Provides a Clinical Update on Mt-601 in Patients With Lymphoma

THOMSON REUTERS
·
19 Dec 2024

Marker Therapeutics Inc - Mt-601 Well Tolerated With No Icans Observed

THOMSON REUTERS
·
19 Dec 2024

BRIEF-Marker Therapeutics Awarded $9.5 Mln Grant From The Cancer Prevention & Research Institute Of Texas (Cprit)

Reuters
·
17 Dec 2024

Marker Therapeutics awarded $9.5M grant from CPRIT

TIPRANKS
·
17 Dec 2024

Marker Therapeutics: Plans to Investigate Its Potential Application Beyond Lymphoma in Patients With Solid Tumors

THOMSON REUTERS
·
17 Dec 2024

Marker Therapeutics Awarded $9.5 Million Grant From the Cancer Prevention & Research Institute of Texas (Cprit) to Support the Investigation of Mt-601 in Patients With Pancreatic Cancer

THOMSON REUTERS
·
17 Dec 2024

Marker Therapeutics Inc: Anticipates Clinical Program Initiation in 2025

THOMSON REUTERS
·
17 Dec 2024

Press Release: Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Dow Jones
·
17 Dec 2024

Marker Therapeutics Leads 3 Noteworthy US Penny Stocks

Simply Wall St.
·
06 Dec 2024

BRIEF-Marker Therapeutics Files For Mixed Shelf Of Up To $300 Million

Reuters
·
28 Nov 2024

Marker Therapeutics Files $300 Million Mixed Shelf

MT Newswires Live
·
28 Nov 2024

Marker Therapeutics Inc Files for Mixed Shelf of up to $300 Mln – SEC Filing

THOMSON REUTERS
·
28 Nov 2024